Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

NSE plans to let you bet on NSE after listing on BSE

The National Stock Exchange of India (NSE) is reportedly considering allowing its shares to trade on its own platform even after listing them on rival BSE Ltd., according to sources familiar with the matter. This move could potentially shift trading volumes and lead to the inclusion of NSE shares in the exchange's benchmark indexes, the Nifty.

The proposal was discussed during recent road shows for NSE's initial public offering (IPO) with global investors, though the details remain private. Under the plan, NSE shares could be classified as "permitted to trade" on BSE despite being formally listed on the exchange. However, the current regulations do not permit self-listing of a stock exchange, and NSE would require approval from the Securities and Exchange Board of India (Sebi) for this arrangement.

Discussions on this matter are ongoing and depend on regulatory approval. Should this become a reality, NSE shares would retain their primary listing on BSE while gaining access to liquidity on both exchanges. Currently, about 250 companies that are not listed on NSE trade on its platform under the "permitted to trade" framework, including companies like Elantas Beck India Ltd., Goodyear India Ltd., and Novartis India Ltd. NSE aims to receive Sebi's approval for its draft prospectus by the end of August and plans to launch its IPO in the second half of September.

Written by urgent.news from The Economic Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at economictimes.indiatimes.com →

More in Finance & Markets

Telix half year revenue increases 22 per cent to 477 million dollars

Radiopharmaceutical manufacturer Telix Pharmaceuticals reported 477 million dollars in half year group revenue on 20 August 2026 boosting gross margin to 55 per cent

  • Telix Pharmaceuticals revenue grew 22% to US$477 million in H1 2026
  • Gross margin improved by 2% to 55%, Precision Medicine margin up 1% to 65%
  • Company invested US$124 million in R&D for late-stage programs and Regeneron collaboration

More from Thursday 20 August →